ORUKA THERAPEUTICS INC (ORKA) — insider trading
Health Care · NASDAQ
ORUKA THERAPEUTICS INC (ORKA) has 155 reported SEC Form 4 insider transactions in our data, including 58 open-market sales among the most recent 100 (latest 2026-10-01).
Recent Form 4 transactions
Showing the 100 most recent of 155 recorded transactions. See all on SEC EDGAR →
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-10-01 | Klein Lawrence Otto | Director, Officer (Chief Executive Officer) | Option exercise / conversion (derivative) | 25,000 | — | $0 | Form 4 |
| 2026-10-01 | Klein Lawrence Otto | Director, Officer (Chief Executive Officer) | Open-market sale | 200 | $84.78 | $17.0K | Form 4 |
| 2026-10-01 | Klein Lawrence Otto | Director, Officer (Chief Executive Officer) | Open-market sale | 8,554 | $84.03 | $718.8K | Form 4 |
| 2026-10-01 | Klein Lawrence Otto | Director, Officer (Chief Executive Officer) | Open-market sale | 16,246 | $83.40 | $1.35M | Form 4 |
| 2026-10-01 | Klein Lawrence Otto | Director, Officer (Chief Executive Officer) | Option exercise / conversion | 25,000 | $7.80 | $195.0K | Form 4 |
| 2026-09-21 | Quinlan Paul T | Officer (General Counsel) | Option exercise / conversion (derivative) | 10,000 | — | $0 | Form 4 |
| 2026-09-21 | Quinlan Paul T | Officer (General Counsel) | Open-market sale | 2,667 | $95.31 | $254.2K | Form 4 |
| 2026-09-21 | Quinlan Paul T | Officer (General Counsel) | Open-market sale | 601 | $94.44 | $56.8K | Form 4 |
| 2026-09-21 | Quinlan Paul T | Officer (General Counsel) | Open-market sale | 3,832 | $93.32 | $357.6K | Form 4 |
| 2026-09-21 | Quinlan Paul T | Officer (General Counsel) | Open-market sale | 2,900 | $92.37 | $267.9K | Form 4 |
| 2026-09-21 | Quinlan Paul T | Officer (General Counsel) | Option exercise / conversion | 10,000 | $7.80 | $78.0K | Form 4 |
| 2026-09-21 | Agarwal Arjun | Officer (Senior Vice President, Finance) | Open-market sale | 533 | $95.75 | $51.0K | Form 4 |
| 2026-09-15 | Quinlan Paul T | Officer (General Counsel) | Open-market sale | 1,039 | $95.71 | $99.4K | Form 4 |
| 2026-09-15 | Sandler Laura Lee | Officer (Chief Operating Officer) | Open-market sale | 906 | $95.71 | $86.7K | Form 4 |
| 2026-09-15 | Klein Lawrence Otto | Director, Officer (Chief Executive Officer) | Open-market sale | 2,452 | $95.71 | $234.7K | Form 4 |
| 2026-09-15 | Goncalves Joana | Officer (Chief Medical Officer) | Option exercise / conversion (derivative) | 3,500 | — | $0 | Form 4 |
| 2026-09-15 | Goncalves Joana | Officer (Chief Medical Officer) | Option exercise / conversion (derivative) | 3,500 | — | $0 | Form 4 |
| 2026-09-15 | Goncalves Joana | Officer (Chief Medical Officer) | Open-market sale | 947 | $95.71 | $90.6K | Form 4 |
| 2026-09-15 | Goncalves Joana | Officer (Chief Medical Officer) | Open-market sale | 100 | $94.22 | $9.4K | Form 4 |
| 2026-09-15 | Goncalves Joana | Officer (Chief Medical Officer) | Open-market sale | 1,366 | $92.99 | $127.0K | Form 4 |
| 2026-09-15 | Goncalves Joana | Officer (Chief Medical Officer) | Open-market sale | 3,150 | $92.03 | $289.9K | Form 4 |
| 2026-09-15 | Goncalves Joana | Officer (Chief Medical Officer) | Open-market sale | 2,384 | $91.10 | $217.2K | Form 4 |
| 2026-09-15 | Goncalves Joana | Officer (Chief Medical Officer) | Option exercise / conversion | 3,500 | $7.80 | $27.3K | Form 4 |
| 2026-09-15 | Goncalves Joana | Officer (Chief Medical Officer) | Option exercise / conversion | 3,500 | $6.84 | $23.9K | Form 4 |
| 2026-09-15 | Agarwal Arjun | Officer (Senior Vice President, Finance) | Open-market sale | 560 | $95.71 | $53.6K | Form 4 |
| 2026-09-11 | Agarwal Arjun | Officer (Senior Vice President, Finance) | Option exercise / conversion (derivative) | 1,459 | — | $0 | Form 4 |
| 2026-09-11 | Agarwal Arjun | Officer (Senior Vice President, Finance) | Option exercise / conversion (derivative) | 8,000 | — | $0 | Form 4 |
| 2026-09-11 | Agarwal Arjun | Officer (Senior Vice President, Finance) | Open-market sale | 200 | $94.02 | $18.8K | Form 4 |
| 2026-09-11 | Agarwal Arjun | Officer (Senior Vice President, Finance) | Open-market sale | 2,208 | $93.26 | $205.9K | Form 4 |
| 2026-09-11 | Agarwal Arjun | Officer (Senior Vice President, Finance) | Open-market sale | 4,051 | $92.41 | $374.4K | Form 4 |
| 2026-09-11 | Agarwal Arjun | Officer (Senior Vice President, Finance) | Open-market sale | 3,000 | $91.11 | $273.3K | Form 4 |
| 2026-09-11 | Agarwal Arjun | Officer (Senior Vice President, Finance) | Option exercise / conversion | 1,459 | $34.39 | $50.2K | Form 4 |
| 2026-09-11 | Agarwal Arjun | Officer (Senior Vice President, Finance) | Option exercise / conversion | 8,000 | $12.50 | $100.0K | Form 4 |
| 2026-09-01 | Klein Lawrence Otto | Director, Officer (Chief Executive Officer) | Option exercise / conversion (derivative) | 75,000 | — | $0 | Form 4 |
| 2026-09-01 | Klein Lawrence Otto | Director, Officer (Chief Executive Officer) | Open-market sale | 4,800 | $92.44 | $443.7K | Form 4 |
| 2026-09-01 | Klein Lawrence Otto | Director, Officer (Chief Executive Officer) | Open-market sale | 63,596 | $91.90 | $5.84M | Form 4 |
| 2026-09-01 | Klein Lawrence Otto | Director, Officer (Chief Executive Officer) | Open-market sale | 6,604 | $90.79 | $599.6K | Form 4 |
| 2026-09-01 | Klein Lawrence Otto | Director, Officer (Chief Executive Officer) | Option exercise / conversion | 75,000 | $7.80 | $585.0K | Form 4 |
| 2026-09-01 | Sandler Laura Lee | Officer (Chief Operating Officer) | Option exercise / conversion (derivative) | 5,000 | — | $0 | Form 4 |
| 2026-09-01 | Sandler Laura Lee | Officer (Chief Operating Officer) | Open-market sale | 4,000 | $92.01 | $368.1K | Form 4 |
| 2026-09-01 | Sandler Laura Lee | Officer (Chief Operating Officer) | Open-market sale | 1,000 | $91.05 | $91.0K | Form 4 |
| 2026-09-01 | Sandler Laura Lee | Officer (Chief Operating Officer) | Option exercise / conversion | 5,000 | $7.80 | $39.0K | Form 4 |
| 2026-08-24 | Edwards Larry Todd | Officer (Chief Commercial Officer) | Grant / award / vesting (derivative) | 20,000 | — | $0 | Form 4 |
| 2026-08-24 | Edwards Larry Todd | Officer (Chief Commercial Officer) | Grant / award / vesting | 100,000 | — | $0 | Form 4 |
| 2026-08-17 | Goncalves Joana | Officer (Chief Medical Officer) | Option exercise / conversion (derivative) | 3,500 | — | $0 | Form 4 |
| 2026-08-17 | Goncalves Joana | Officer (Chief Medical Officer) | Option exercise / conversion (derivative) | 3,500 | — | $0 | Form 4 |
| 2026-08-17 | Goncalves Joana | Officer (Chief Medical Officer) | Open-market sale | 2,480 | $112.56 | $279.2K | Form 4 |
| 2026-08-17 | Goncalves Joana | Officer (Chief Medical Officer) | Open-market sale | 3,320 | $112.01 | $371.9K | Form 4 |
| 2026-08-17 | Goncalves Joana | Officer (Chief Medical Officer) | Open-market sale | 300 | $110.52 | $33.2K | Form 4 |
| 2026-08-17 | Goncalves Joana | Officer (Chief Medical Officer) | Open-market sale | 900 | $109.65 | $98.7K | Form 4 |
| 2026-08-17 | Goncalves Joana | Officer (Chief Medical Officer) | Option exercise / conversion | 3,500 | $7.80 | $27.3K | Form 4 |
| 2026-08-17 | Goncalves Joana | Officer (Chief Medical Officer) | Option exercise / conversion | 3,500 | $6.84 | $23.9K | Form 4 |
| 2026-08-14 | Quinlan Paul T | Officer (General Counsel) | Option exercise / conversion (derivative) | 42,000 | — | $0 | Form 4 |
| 2026-08-14 | Quinlan Paul T | Officer (General Counsel) | Option exercise / conversion (derivative) | 10,000 | — | $0 | Form 4 |
| 2026-08-14 | Quinlan Paul T | Officer (General Counsel) | Open-market sale | 3,847 | $111.14 | $427.5K | Form 4 |
| 2026-08-14 | Quinlan Paul T | Officer (General Counsel) | Open-market sale | 9,193 | $110.00 | $1.01M | Form 4 |
| 2026-08-14 | Quinlan Paul T | Officer (General Counsel) | Open-market sale | 10,200 | $109.11 | $1.11M | Form 4 |
| 2026-08-14 | Quinlan Paul T | Officer (General Counsel) | Open-market sale | 14,696 | $107.97 | $1.59M | Form 4 |
| 2026-08-14 | Quinlan Paul T | Officer (General Counsel) | Open-market sale | 10,434 | $107.14 | $1.12M | Form 4 |
| 2026-08-14 | Quinlan Paul T | Officer (General Counsel) | Open-market sale | 3,630 | $106.05 | $385.0K | Form 4 |
| 2026-08-14 | Quinlan Paul T | Officer (General Counsel) | Option exercise / conversion | 42,000 | $12.50 | $525.0K | Form 4 |
| 2026-08-14 | Quinlan Paul T | Officer (General Counsel) | Option exercise / conversion | 10,000 | $7.80 | $78.0K | Form 4 |
| 2026-08-13 | Agarwal Arjun | Officer (Senior Vice President, Finance) | Option exercise / conversion (derivative) | 1,458 | — | $0 | Form 4 |
| 2026-08-13 | Agarwal Arjun | Officer (Senior Vice President, Finance) | Option exercise / conversion (derivative) | 8,542 | — | $0 | Form 4 |
| 2026-08-13 | Agarwal Arjun | Officer (Senior Vice President, Finance) | Open-market sale | 2,358 | $108.46 | $255.8K | Form 4 |
| 2026-08-13 | Agarwal Arjun | Officer (Senior Vice President, Finance) | Open-market sale | 2,142 | $107.71 | $230.7K | Form 4 |
| 2026-08-13 | Agarwal Arjun | Officer (Senior Vice President, Finance) | Open-market sale | 1,268 | $106.63 | $135.2K | Form 4 |
| 2026-08-13 | Agarwal Arjun | Officer (Senior Vice President, Finance) | Open-market sale | 2,132 | $105.57 | $225.1K | Form 4 |
| 2026-08-13 | Agarwal Arjun | Officer (Senior Vice President, Finance) | Open-market sale | 2,100 | $104.67 | $219.8K | Form 4 |
| 2026-08-13 | Agarwal Arjun | Officer (Senior Vice President, Finance) | Option exercise / conversion | 1,458 | $34.39 | $50.1K | Form 4 |
| 2026-08-13 | Agarwal Arjun | Officer (Senior Vice President, Finance) | Option exercise / conversion | 8,542 | $12.50 | $106.8K | Form 4 |
| 2026-07-15 | Goncalves Joana | Officer (Chief Medical Officer) | Option exercise / conversion (derivative) | 3,500 | — | $0 | Form 4 |
| 2026-07-15 | Goncalves Joana | Officer (Chief Medical Officer) | Option exercise / conversion (derivative) | 3,500 | — | $0 | Form 4 |
| 2026-07-15 | Goncalves Joana | Officer (Chief Medical Officer) | Open-market sale | 300 | $87.25 | $26.2K | Form 4 |
| 2026-07-15 | Goncalves Joana | Officer (Chief Medical Officer) | Open-market sale | 3,803 | $86.68 | $329.6K | Form 4 |
| 2026-07-15 | Goncalves Joana | Officer (Chief Medical Officer) | Open-market sale | 2,497 | $85.86 | $214.4K | Form 4 |
| 2026-07-15 | Goncalves Joana | Officer (Chief Medical Officer) | Open-market sale | 400 | $84.37 | $33.7K | Form 4 |
| 2026-07-15 | Goncalves Joana | Officer (Chief Medical Officer) | Option exercise / conversion | 3,500 | $7.80 | $27.3K | Form 4 |
| 2026-07-15 | Goncalves Joana | Officer (Chief Medical Officer) | Option exercise / conversion | 3,500 | $6.84 | $23.9K | Form 4 |
| 2026-07-13 | Agarwal Arjun | Officer (Senior Vice President, Finance) | Option exercise / conversion (derivative) | 1,458 | — | $0 | Form 4 |
| 2026-07-13 | Agarwal Arjun | Officer (Senior Vice President, Finance) | Option exercise / conversion (derivative) | 8,541 | — | $0 | Form 4 |
| 2026-07-13 | Agarwal Arjun | Officer (Senior Vice President, Finance) | Open-market sale | 300 | $85.63 | $25.7K | Form 4 |
| 2026-07-13 | Agarwal Arjun | Officer (Senior Vice President, Finance) | Open-market sale | 5,656 | $84.90 | $480.2K | Form 4 |
| 2026-07-13 | Agarwal Arjun | Officer (Senior Vice President, Finance) | Open-market sale | 3,743 | $84.26 | $315.4K | Form 4 |
| 2026-07-13 | Agarwal Arjun | Officer (Senior Vice President, Finance) | Open-market sale | 300 | $83.07 | $24.9K | Form 4 |
| 2026-07-13 | Agarwal Arjun | Officer (Senior Vice President, Finance) | Option exercise / conversion | 1,458 | $34.39 | $50.1K | Form 4 |
| 2026-07-13 | Agarwal Arjun | Officer (Senior Vice President, Finance) | Option exercise / conversion | 8,541 | $12.50 | $106.8K | Form 4 |
| 2026-07-01 | Sandler Laura Lee | Officer (Chief Operating Officer) | Option exercise / conversion (derivative) | 5,000 | — | $0 | Form 4 |
| 2026-07-01 | Sandler Laura Lee | Officer (Chief Operating Officer) | Open-market sale | 500 | $95.47 | $47.7K | Form 4 |
| 2026-07-01 | Sandler Laura Lee | Officer (Chief Operating Officer) | Open-market sale | 2,263 | $94.75 | $214.4K | Form 4 |
| 2026-07-01 | Sandler Laura Lee | Officer (Chief Operating Officer) | Open-market sale | 2,237 | $93.85 | $209.9K | Form 4 |
| 2026-07-01 | Sandler Laura Lee | Officer (Chief Operating Officer) | Option exercise / conversion | 5,000 | $7.80 | $39.0K | Form 4 |
| 2026-07-01 | Fairmount Funds Management LLC; Fairmount Healthcare Fund II L.P.; Fairmount Healthcare Co-Invest III L.P.; Kiselak Tomas; Harwin Peter Evan | Director, 10% owner | Conversion of derivative (derivative) | 42,641 | — | $0 | Form 4 |
| 2026-07-01 | Fairmount Funds Management LLC; Fairmount Healthcare Fund II L.P.; Fairmount Healthcare Co-Invest III L.P.; Kiselak Tomas; Harwin Peter Evan | Director, 10% owner | Open-market sale | 3,553,410 | $84.43 | $300.01M | Form 4 |
| 2026-07-01 | Fairmount Funds Management LLC; Fairmount Healthcare Fund II L.P.; Fairmount Healthcare Co-Invest III L.P.; Kiselak Tomas; Harwin Peter Evan | Director, 10% owner | Conversion of derivative | 3,553,410 | — | — | Form 4 |
| 2026-06-22 | Agarwal Arjun | Officer (Senior Vice President, Finance) | Open-market sale | 699 | $82.15 | $57.4K | Form 4 |
| 2026-06-22 | Agarwal Arjun | Officer (Senior Vice President, Finance) | Open-market sale | 888 | $80.01 | $71.0K | Form 4 |
| 2026-06-15 | Quinlan Paul T | Officer (General Counsel) | Open-market sale | 733 | $69.69 | $51.1K | Form 4 |
| 2026-06-15 | Sandler Laura Lee | Officer (Chief Operating Officer) | Open-market sale | 600 | $69.69 | $41.8K | Form 4 |
| 2026-06-15 | Klein Lawrence Otto | Director, Officer (Chief Executive Officer) | Open-market sale | 1,729 | $69.69 | $120.5K | Form 4 |
Ask the chat about ORKA's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: ORUKA THERAPEUTICS INC (ORKA).
Last updated 2026-10-01 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.